Filing Flows › Spero Therapeutics (SPRO) › Q1 2026
Spero Therapeutics (SPRO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Spero Therapeutics (SPRO) reported revenue of $258K for the first quarter 2026 (Q1 2026), -96% from a year earlier and -99% from the quarter before.
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $258K | -99% | -96% |
| Operating profit | −$7.5M | -124% | — |
| Net earnings | −$7.2M | -123% | — |
| Operating cash flow | $15.9M | — | — |
What changed
Revenue was $258K in Q1 2026, down 96% year over year and down 99% from the previous quarter.
Operating costs exceeded revenue by $7.5M, an operating margin of -2921.7%. Total costs fell 62% while revenue fell 96%. The quarter ended with a net loss of $7.2M, after a profit of $31.5M the previous quarter.
Operating cash flow was $15.9M. Non-cash charges added back $1.1M of share-based compensation. Working capital and other items added $22.0M.
Questions
What was Spero Therapeutics' revenue in the first quarter 2026?
Spero Therapeutics (SPRO) reported revenue of $258K for the first quarter 2026 (Q1 2026), -96% from a year earlier and -99% from the quarter before.
Source: Spero Therapeutics 10-Q on SEC EDGAR.